- Trial phase
- Preclinical / IND-enabling
- Time to market
- IND filing planned for Q4 2027; if approved, earliest commercialization would be many years away, contingent on successful Phase 1, Phase 2, and Phase 3 trials.
- Why 2/10
- XTX602 is a preclinical candidate with no hard binary catalyst in the next ~12 months; the next scheduled milestone is an IND filing in Q4 2027, roughly a year away, and XTX602 is not Xilio's lead asset (that is XTX501, whose Phase 1 data are due Q4 2027).
The next catalyst for XTX602 is an IND filing planned for Q4 2027, which is roughly 12 months away. The nearer-term drivers for XLO stock are the Gilead option decision on XTX301 (H1 2027) and initial Phase 1 data for lead asset XTX501 (Q4 2027). Until XTX602 enters the clinic, investors will value XLO primarily on XTX501 progress and partnership outcomes.
Price Chart
Executive Summary
XTX602 is a preclinical-stage masked immuno-oncology candidate from Xilio Therapeutics (Nasdaq: XLO), a ~$58M market-cap biotech. The drug's mechanism has not been publicly specified, but Xilio's pipeline uses a \"masked\" platform designed to activate immune therapies only inside tumors. XTX602 is an early-stage pipeline program; the company plans to file an IND in Q4 2027, roughly 12 months away. Xilio's lead asset is XTX501 (Phase 1/2, PD-1/masked IL-2 bispecific), and its most advanced partnered asset is XTX301 (licensed to Gilead). With no approved products, the stock trades entirely on pipeline progress and partnership outcomes.
How It Works
Xilio develops \"masked\" immunotherapies that are designed to remain inactive until they reach the tumor environment, potentially reducing side effects compared to traditional immune-stimulating drugs. XTX602 is a preclinical-stage candidate from this platform, though its specific molecular target and mechanism have not been publicly detailed. Based on Xilio's pipeline descriptions, it is likely a multi-specific, masked T cell engager (an engineered antibody that directs immune T cells to attack cancer cells) targeting tumor-associated antigens.
Trial Status
XTX602 is in IND-enabling studies. Xilio's Q3 2026 earnings press release listed XTX602 as an advancing pipeline program with an IND submission targeted for Q4 2027. No clinical trials have been initiated.
The Two-Sided Case
Upcoming Catalysts
- IND filing for XTX602 targeted for Q4 2027
- Gilead option decision on XTX301 (tumor-activated IL-12) expected H1 2027
- Initial Phase 1 data for lead asset XTX501 expected Q4 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xilio Therapeutics, Inc. PRESS-RELEASE XLO ·Originating report